Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00130338
Status:
COMPLETED
Last Update Posted:
2017-03-28
First Post:
2005-08-11
Brief Title:
Rivastigmine Capsules in Patients With Probable Vascular Dementia
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this research study is to evaluate in the open-label extension phase the effectiveness tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None